Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Diluted Average) (2021 - 2026)

C4 Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $126.1 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 77.99% year-over-year to $126.1 million; the TTM value through Mar 2026 reached $126.1 million, up 77.99%, while the annual FY2025 figure was $82.9 million, 19.49% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $126.1 million at C4 Therapeutics, up from $82.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $126.1 million in Q1 2026 and troughed at $48.7 million in Q1 2022.
  • A 5-year average of $64.2 million and a median of $68.4 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 0.37% in 2023 and later skyrocketed 77.99% in 2026.
  • Year by year, Shares Outstanding (Diluted Average) stood at $48.9 million in 2022, then grew by 1.59% to $49.6 million in 2023, then skyrocketed by 39.75% to $69.4 million in 2024, then grew by 19.49% to $82.9 million in 2025, then skyrocketed by 52.09% to $126.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CCCC at $126.1 million in Q1 2026, $82.9 million in Q4 2025, and $72.6 million in Q3 2025.